Bevacizumab for front-Line Treatment of Epithelial Ovarian, Fallopian tube or Primary Peritoneal Cancer Patients With High Risk of Relapse- a Cost Effective option for Canadian Patients
May 1, 2015, 00:00
10.1016/j.jval.2015.03.1168
https://www.valueinhealthjournal.com/article/S1098-3015(15)01225-5/fulltext
Title :
Bevacizumab for front-Line Treatment of Epithelial Ovarian, Fallopian tube or Primary Peritoneal Cancer Patients With High Risk of Relapse- a Cost Effective option for Canadian Patients
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(15)01225-5&doi=10.1016/j.jval.2015.03.1168
First page :
A202
Section Title :
Cancer
Open access? :
No
Section Order :
633